Although it may seem paradoxical, our results suggested that SLC25, and in particular, SLC25A5 and SLC25A24, might be involved in the EGFR and ERK-MAPK signaling pathways in colon cancer and potentially serve as treatment targets. Here, EGFR is linked to colonic neoplasm.